Open access · OA
via OpenAlex
Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions
Bhawana Singh, Oleg A. Karpov, Manuel Mayr
Atherosclerosis · 2026 · ▲ 7 citations
Abstract
BACKGROUND AND AIMS: Commercial high-throughput proteomics platforms, such as Olink and SomaLogic, enable large-scale epidemiological studies with integrated multi-omics measurements. While these proteomics approaches have been widely applied in biobanks, issues of data quality remain underappreciated. In this review, we discuss these limitations and outline a way forward for realizing the clinical translation of proteomics as a comprehensive 'liquid health check'. METHODS: We reviewed the recent literature for artificial intelligence (AI) and multi-omics, particularly proteomics in atherosclerotic cardiovascular disease (ASCVD). RESULTS: AI-driven multi-omics analyses have the potential to advance our understanding of multifactorial causes of ASCVD, including aging. Emerging concepts such as "ageotypes" suggest the potential for personalized intervention to slow aging processes. Commercial proteomics platforms have accelerated biomarker discovery in ASCVD, but challenges remain in clinical translation. Limited correlation between Olink and SomaLogic necessitates orthogonal validation of findings. Platform-specific issues, such as epitope effects and cross-reactivity, can yield divergent protein quantitative trait loci for the same protein, complicating causal inference. While tissue proteomics provides complementary insights to plasma proteomics, reliance on autopsy samples raises concerns about protein degradation and measurement reliability. Increasingly, single-cell and spatial proteomics are being explored to better capture plaque heterogeneity, complementing bulk proteomics in larger cohorts. CONCLUSION: Beyond risk prediction, proteomics offers opportunities to elucidate disease mechanisms and enable drug repurposing. To realize the clinical potential of plasma proteomics, absolute or reliably recalibratable relative quantification will be required to guide patient care. Ultimately, the clinical value of proteomics will be determined by the quality rather than the quantity of protein measurements.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.atherosclerosis.2026.120637
- Canonical
- link ↗
- Fetched
- 2026-10-14 MST
Cite this
APA
Singh, B., Karpov, O.A., & Mayr, M. (2026). Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions. <em>Atherosclerosis</em>. https://doi.org/10.1016/j.atherosclerosis.2026.120637
Vancouver
Singh B, Karpov OA, Mayr M. Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions. Atherosclerosis. 2026. doi:10.1016/j.atherosclerosis.2026.120637.
BibTeX
@article{bhawana2026Clinic,
title = {Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions},
author = {Bhawana Singh and Oleg A. Karpov and Manuel Mayr},
journal = {Atherosclerosis},
year = {2026},
doi = {10.1016/j.atherosclerosis.2026.120637},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Revista de investigaci�n Cl�nica 2026
Open access · CC-BY
Biological aging clocks as biomarkers of human aging: Biological basis, methodological design, and epidemiological implications
Nutrients 2026
Open access · CC-BY
Dietary Polyphenols in Brain Aging: Molecular Mechanisms and Implications for Neurodegeneration
Cardiovascular Diabetology 2025
Open access · CC-BY
Proteomics mediates the effects of biological aging on the progression of cardio-renal-metabolic comorbidity: a UK biobank cohort study
Alimentary Pharmacology & Therapeutics 2025
Open access · CC-BY
Diagnostics of Autoimmune Hepatitis Enabled by Non‐Invasive Clinical Proteomics
Degenerative Neurological and Neuromuscular Disease 2026
Open access · CC-BY
Spermidine in Alzheimer’s Disease: Evidence from Animal Models and Human Studies
African Journal of Biomedical Research 2026
Open access · CC-BY